SCHEMBL12907412

SCHEMBL12907412

Cc1n[nH]c2ccc(-c3ccccc3Oc3ccccc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 4/20 0.46
▸ MKNK1 Q9BUB5 1/20 0.45
▸ PTGS2 P35354 1/20 0.44
▸ JAK2 O60674 2/20 0.43
▸ LRRK2 Q5S007 2/20 0.43
▸ JAK1 P23458 1/20 0.43
▸ TYK2 P29597 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ CAMKK2 Q96RR4 2/20 0.42
▸ MAPK13 O15264 1/20 0.41
▸ GCGR P47871 1/20 0.41
▸ MAPK12 P53778 1/20 0.41
▸ MAPK11 Q15759 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ CHEK1 O14757 1/20 0.41
▸ CDK4 P11802 1/20 0.41
▸ CCNA2 P20248 1/20 0.41
▸ CCND1 P24385 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ CCND3 P30281 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907425 0.90 CHEK1 (0.48) BRD4PTGS2JAK2CAMKK2MAPK13
SCHEMBL12907173 0.85 JAK2 (0.60) JAK2LRRK2JAK1TYK2JAK3
SCHEMBL12907191 0.77 JAK2 (0.60) MKNK1JAK2JAK1TYK2JAK3
SCHEMBL27968550 0.77 MKNK1 (0.71) MKNK1JAK2CHEK1CDK4CCNA2
SCHEMBL12907440 0.76 JAK2 (0.48) MKNK1JAK2JAK1TYK2JAK3
SCHEMBL12907416 0.73 CHEK1 (0.49) MKNK1JAK2JAK1TYK2JAK3
SCHEMBL27565878 0.73 MKNK1 (0.57) MKNK1JAK2MAPK14CHEK1CDK4
SCHEMBL12907469 0.72 JAK2 (0.53) MKNK1JAK2CHEK1CDK4CCNA2
SCHEMBL18190547 0.72 BRD4 (0.50) BRD4PTGS2ABL1FFAR4NCOA1
SCHEMBL12907240 0.71 JAK2 (0.63) JAK2JAK1TYK2JAK3SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 — — US disclosed
Send feedback